Fariba Shirvani

Fariba Shirvani

Auto-generated profile, based on publicly available information

Fariba Shirvani

Pediatric Infections Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2016 in Jundishapur Journal of Microbiology
Verified
Journal Article
Open access
PDF file
KSKimia Seifi
Kimia Seifi
HKHossein Kazemian
Hossein Kazemian
HHHamid Heidari
Hamid Heidari
FRFereshteh Rezagholizadeh
Fereshteh Rezagholizadeh
YSYasaman Saee
Yasaman Saee
HHHamidreza Houri
Hamidreza Houri
Background: Klebsiella pneumoniae is among the most frequently recovered etiologic agents from nosocomial infections. This opportunistic pathogen can generate a thick layer of biofilm as one of its important virulence factors, enabling the bacteria to attach to living or abiotic surfaces, which contributes to drug resistance. Objectives: The resistance of biofilm-mediated infections to effective chemotherapy has adverse effects on patient outcomes and survival. Therefore, the aim of the present study was to evaluate the biofilm-formation capacity of clinical K. pneumoniae isolates and to perform a molecular characterization using enterobacterial repetitive intergenic consensus-polymerase chain reaction (ERIC-PCR) to determine the dominant biofilm-producing genotype. Patients and Methods: In the present study, 94 K. pneumoniae isolates were obtained from two hospitals in Tehran, Iran. Biofilm formation was assayed by a modified procedure, then ERIC-PCR was carried out. Results: The distributions of the clinical specimens used in this study were 61.7% from urine, 18.1% from wounds, 11.7% from sputum, and 8.5% from blood. Among these isolates, 33% formed fully established biofilms, 52.1% were categorized as moderately biofilm-producing, 8.5% formed weak biofilms, and 6.4% were non-biofilm-producers. Genotyping of K. pneumoniae revealed 31 different ERIC types. Biofilm-formation ability in a special ERIC type was not observed. Conclusions: Our results indicated that an enormous proportion of K. pneumoniae isolated from sputum and surgical-wound swabs produced fully established biofilms. It is reasonable to assume the existence of a relationship between the site of infection and the formation of biofilm. A high level of genetic diversity among the K. pneumoniae strains was observed. Keywords: Biofilm; PCR; Klebsiella pneumonia


27 October 2015 in Archives of Pediatric Infectious Diseases
Verified
Journal Article
Open access
PDF file
SAShahnaz Armin
Shahnaz Armin
AKAbdollah Karimi
Abdollah Karimi
FFFatemeh Fallah
Fatemeh Fallah
STSedighe Rafiei Tabatabaii
Sedighe Rafiei Tabatabaii
SASeyedeh Mahsan Hoseini Alfatemi
Seyedeh Mahsan Hoseini Alfatemi
RNRaheleh Sadat Sajadi Nia
Raheleh Sadat Sajadi Nia
Background: Nosocomial infections constitute a global health problem, leading to a high rate of morbidity and mortality. The choice of antimicrobial treatment for nosocomial infections is often empirical and based on the knowledge of local antimicrobial activity patterns of the most common bacteria causing such infections. Objectives: The aim of this study was to determine the 3 most prevalent bacterial pathogens including Acinetobacter baumannii, Pseudomonas aeruginosa and Staphylococcus aureus causing nosocomial infections and their antimicrobial resistant profiles in patients admitted to three hospitals in Tehran city, Iran. Materials and Methods: In this cross-sectional study, the A. baumannii, P. aeruginosa and S. aureus isolates were obtained from different samples of patients with nosocomial infections admitted to different wards of three hospitals including Milad, Motahary and Loghman from November 2014 to April 2015. Nosocomial infections were defined as a culture-proven infection, which occurred more than 48 hours after admission. Antimicrobial susceptibility testing was performed using the disk diffusion method according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Results: In total, 539 samples were collected during the study period from patients with nosocomial infections. Overall, 198, 75 and 98 A. baumannii, P. aeruginosa and S. aureus isolates were obtained, respectively. Cefepim and meropenem were found to be the most effective antibiotics for nosocomial infections caused by S. aureus with only 1 resistant isolate. Resistance to gentamicin and amikacin and susceptibility to cefepim was the highest compared to other antibiotics amongst P. aeruginosa isolates which is in consistent with the fact that cephalosporins remain useful agents for the management of nosocomial infections caused by P. aeruginosa. Acinetobacter baumannii isolates showed lower susceptibility rates to imipenem and ciprofloxacin than other antibiotics with 189 and 187 resistant isolates, respectively; however 155 isolates were susceptible to co-trimoxazole and ceftazidime. The high resistant rate amongst A. baumannii to carbapenems is likely consequence of heavy empirical usage of this group of antibiotics. Conclusions: The high prevalence of antimicrobial resistance in the hospitals highlights the need for further infection control programs. Future regional epidemiological data on antimicrobial resistance patterns will be required to implement strict national antibiotic policies to restrict the spread of these resistance bugs. Keywords: Nosocomial Infection; A. baumannii; P. aeruginosa; S. aureus; Antimicrobial Drug Resistance

CMChristine Maure
Christine Maure
VEVaralakshmi Elango
Varalakshmi Elango
SBSteven Black
Steven Black
SPSilvia Perez-Vilar
Silvia Perez-Vilar
JCJose Luis Castro
Jose Luis Castro
CZCarlos Zunino
Carlos Zunino

15 December 2021 in Canadian Journal of Infectious Diseases and Medical Microbiology
Verified
Journal Article
Open access
PDF file
SAShahnaz Armin
Shahnaz Armin
MMMohammadreza Mirkarimi
Mohammadreza Mirkarimi
ZPZahra Pourmoghaddas
Zahra Pourmoghaddas
MTMarjan Tariverdi
Marjan Tariverdi
AJAzadeh Jafrasteh
Azadeh Jafrasteh
SHSeyedeh Mahsan Hoseini-Alfatemi
Seyedeh Mahsan Hoseini-Alfatemi
Background. Despite the worldwide spread of Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2), information about the epidemiological and clinical patterns of this infection is still largely unknown in children. In addition, the prevalence of this disease is still very high in some parts of the world, including Iran. Thus, this study aims to evaluate the epidemiological features, laboratory and imaging findings, and the type of treatments in children with novel coronavirus 2019 (COVID-19). Method. This study is conducted from March 2020March 2021 by using the medical records of hospitalized confirmed COVID-19 children younger than 18 years in five cities of Iran: Tehran, Ahwaz, Isfahan, Bandar-Abbas, and Khorramabad. In addition to demographic and epidemiological data, we also studied clinical signs and treatments. Results. In total 278 confirmed COVID-19 children, the average age was 5.3 years, and 59.4were boys. A total of 37.8 had an underlying disease, in which the most common was a malignancy. The most common symptoms were fever and cough. In this group of pediatrics, some abnormal laboratory findings have been seen. GGO (Ground-Glass Opacity) had been diagnosed in 58.6 of children. 3.6 needed oxygen therapy with ventilators, and 83.09 had received antibiotic treatments with the majority of ceftriaxone. Also, 10 had got steroids. In this study, the mortality rate was 4.3. Conclusion. In this study, most of the children who died had an underlying disease, so timely care and action is important in them. Most children admitted to our study received antibiotics and were prescribed antivirals and steroids for a smaller number. Also, a small number of children received oxygen therapy, most of whom were in the age group of 1 to 5 years.

11 June 2014 in International Journal of Immunogenetics
Verified
Journal Article
Closed access
PDF file
MZM. Zamani
M. Zamani
MMM. Modares‐Sadegi
M. Modares‐Sadegi
FSF. Shirvani
F. Shirvani
HZH. Zamani
H. Zamani
MEM. H. Emami
M. H. Emami